key: cord-0730744-7fgjoqgb authors: El-Tholoth, Mohamed; Bau, Haim H.; Song, Jinzhao title: A Single and Two-Stage, Closed-Tube, Molecular Test for the 2019 Novel Coronavirus (COVID-19) at Home, Clinic, and Points of Entry date: 2020-02-19 journal: ChemRxiv DOI: 10.26434/chemrxiv.11860137.v1 sha: 64430e253949af8714f34c32b953f61a32dd6faa doc_id: 730744 cord_uid: 7fgjoqgb The 2019 novel coronavirus (COVID-19) is a newly emerged strain that has never been found in humans before. At present, the laboratory-based reverse transcription-polymerase chain reaction (RT-PCR) is the main method to confirm COVID-19 infection. The intensification of the COVID-19 epidemic overwhelms limited clinical resources in particular, but not only, in developing countries, resulting in many patients not being tested for the infection and in large queues of potentially infected individuals waiting to be tested while providing a breeding ground for the disease. We describe here a rapid, highly sensitive, point-of-care, molecular test amenable for use at home, in the clinic, and at points of entry by minimally trained individuals and with minimal instrumentation. Our test is based on loop mediated isothermal amplification (COVID-19 LAMP) and for higher sensitivity on nested nucleic acid, two stage isothermal amplification (COVID-19 Penn-RAMP). Both tests can be carried out in closed tubes with either fluorescence or colorimetric (e.g., leuco crystal violet LCV) detection. COVID-19 LAMP performs on par with COVID-19 RT-PCR. COVID-19 RAMP has 10 fold better sensitivity than COVID-19 LAMP and COVID-19 RT-PCR when testing purified targets and 100 times better sensitivity than COVID-19 LAMP and COVID-19 RT-PCR when testing rapidly prepared sample mimics. Due to fortunate scarcity of COVID-19 infections in the USA, we were not able to test our assays and methods with patient samples. We hope that such tests will be carried out by colleagues in impacted countries. Our Closed-Tube Penn-RAMP has the potential to significantly reduce false negatives while being amenable to use with minimal instrumentation and training. Coronaviruses are a large family of RNA viruses including HCoV-229E, OC43, NL63, and HKU1 that usually cause mild respiratory illnesses (1, 2) with the exceptions of the fatal Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) (3, 4) and Middle East Respiratory Syndrome Coronavirus (MERS) (5) of the last two decades. The 2019 novel coronavirus was discovered due to Wuhan Viral Pneumonia cases in 2019, and was named "COVID-19" by the World Health Organization (6) . The COVID-19 is a newly emerged coronavirus that has never been found in humans before. Since December 2019, Wuhan City, Hubei Province has maintained surveillance of "influenza and related diseases," and identified multiple cases of viral pneumonia with high mortality rate. The World Health Organization has classified the COVID-19 outbreak as "Public Health Emergency of International Concern" (7). Reverse transcription-PCR (RT-PCR) kits have been rapidly developed for the qualitative detection of the COVID-19 in nasopharyngeal swabs, alveolar lavage fluid, sputum, and blood samples (8) . However, RT-PCR tests require well-equipped laboratories and skilled personnel. The growing number of suspected cases exceeds the capacity of many hospitals, leaving many patients untested challenging to the control of the disease. A rapid, point -of -care molecular diagnostics for the COVID-19 is urgently needed. We report here on simple closed-tube molecular tests for COVID-19 that can be carried out at home and in the clinic by minimally trained personnel without a need for sophisticated equipment. Using bioinformatics, we have identified highly conserved sequences in the COVID-19 and we have designed primers targeting the open reading frame 1ab (ORF1ab) gene of the COVID-19 RNA. Previously, we have shown that RT-LAMP successfully detects pathogen nucleic acids with either bioluminescent indicator and smartphone (9) or colorimetrically and with minimal instrumentation (10) . Since many COVID-19 infected individuals are reported negative in the commonly used RT-PCR test, we address the need for a higher sensitivity test with our two-stage isothermal method, dubbed Penn-RAMP (11) . We have originally developed Penn-RAMP to enable high level of multiplexing, but surreptitiously discovered that, in many cases, our two-stage method is 10 times more sensitive than LAMP and PCR when processing purified nucleic acids and 100 times more sensitive than LAMP and RT-PCR with minimally processed samples. Since at the time of writing this paper, only a very small number of COVID-19 cases have been identified in the USA, we have not been able to test our assay with actual patient samples. Given the simplicity and promise of our test, we hope that colleagues in endemic regions will test our assays with actual samples. Complete genome sequences of various COVID-19 (Table S1 ) were aligned and analyzed to identify conserved sequences using Clustal X (http://www.clustal.org/clustal2/) and then compared with sequences of other coronaviruses ( Table S1) . We selected to target the conserved sequence of ORF1ab because of its high homology among COVID-19s sequences and high divergence from all the other coronaviruses examined. Our LAMP primer set ( RNAs of coronaviruses from different genera [Alphacoronavirus (PEDV and TGEV); Gammacoronavirus (IBV); and Deltacoronavirus (PDCoV)] that are available in our lab were used as negative controls to test the specificity of our newly developed LAMP assay. The gold standard RT-PCR currently used for routine tests of COVID-19 in Chinese laboratories was developed by the Chinese Center for Disease Control and Prevention (Chinese CDC) (12) . The PCR primers and TaqMan probe for our qPCR test were synthesized by IDT (Table S3) . Each qPCR reaction mix contained 1 X PrimeTime ® Gene Expression Master Mix (IDT), 400 nM of each PCR primer, 250 nM of TaqMan probe, and 1 µL of synthesized COVID-19 target (Table S2) . qPCR was carried out with a Thermal Cycler (BioRad, Model CFD3240) with a temperature profile of 95°C for 3 min, followed by 50 cycles of amplification (95°C for 15 s and 60°C for 1 min). Penn-RAMP consists of two isothermal amplification processes: Since Our COVID-19 LAMP successfully detected fewer than 100 targets per reaction volume, comparable to COVID-19 PCR (Fig. 1) albeit with somewhat shorter time. The threshold times of our LAMP assay (Fig. 1A) correlated linearly ( Fig. 1D ) with template concentration, indicating that our assay is quasiquantitative and can be used for disease progression monitoring. In contrast to PCR, our LAMP assay is incubated at a fixed temperature (63°C) greatly simplifying instrumentation and reducing power consumption. Indeed, the LAMP assay can be incubated with an exothermic chemical reaction in the absence of electrical power (9, 10). Only samples containing COVID-19 exhibited a positive signal (Fig. 2) . Our test does not exhibit any false positives. Our COVID-19 Closed-Tube Penn-RAMP Assay (Fig. 1) shows that as low as 7 copies of COVID-19 target can be readily detected by one-tube Penn-RAMP, while less than 70 copies of COVID-19 target cannot be detected by LAMP and RT-PCR, showing that the sensitivity of our one-tube Penn-RAMP is 10 times higher than LAMP and RT-PCR. Currently, for the patients with low viral load, due to insufficient detection sensitivity of RT-PCR, many false negative results and so-called "relapse after negative"cases were reported (14) . It is very likely our one-tube Penn-RAMP method can alleviate this situation with its higher sensitivity. Both COVID-19 LAMP and COVID-19 Closed-Tube Penn-RAMP can be carried out with minimal sample preparation at home and in settings with rudimentary equipment. Minimally invasive sample collection is desired for home and field testing. We selected to use nasal swabs consistent with the common sampling method in endemic regions. In the absence of clinical COVID-19 samples, we contrived samples by spiking inactivated HIV viral particles into the nasal swab after nasal mucosa collection. The objective of the experiment is to determine whether we can minimize polymerase inhibition with minimal sample preparation such as eluting the swab into water and heating. We measured the amplification threshold time as a function of sample incubation time and incubation temperature and determined that incubation for over 15 min at temperature above 65°C is enough to lyse the virus and suppress inhibitors ( Figure S1 ) with a relatively small increase in threshold time and reduced reproducibility ( Figure S2 ). The rapid sample preparation may not be adequate for quantification; but is good enough to confirm infection. Rapid sample preparation with COVID-19 LAMP and COVID-19 PCR provided 100% sensitivity at 700 viral particles per reaction and 75% sensitivity at 70 viral copies per reaction ( Table 2 ). In contrast, COVID-19 Closed-Tube Penn-RAMP provided 100% sensitivity at 7 virions per reaction. COVID-19 Closed-Tube Penn-RAMP appears to have much greater tolerance to inhibitors than either PCR or LAMP, performing with minimally prepared samples nearly as well as with purified samples. Visual detection does not require any instrumentation and therefore is desired for diagnostic systems for home use. The LCV dye is nearly colorless in the absence of dsDNA and deep violet in presence of dsDNA, enabling detection of amplicons. We included LCV in the LAMP reaction mix in our Closed-Tube Penn-RAMP assay (Fig. 3A) . The process was carried out with 70 µL of LAMP mix and manual flipping of the tube (without any centrifugation), demonstrating successful instrument-free detection of as few as 100 targets per reaction. Epidemiology and clinical presentations of the four human coronaviruses 229e, hku1, nl63, and oc43 detected over 3 years using a novel multiplex real-time pcr method Epidemiology and clinical characteristics of human coronaviruses oc43, 229e, nl63, and hku1: A study of hospitalized children with acute respiratory tract infection in guangzhou, china Consensus document on the epidemiology of severe acute respiratory syndrome ( sars) . World health organization Responding to global infectious disease outbreaks: Lessons from sars on the role of risk perception, communication and management Middle east respiratory syndrome Surveillance case definitions for human infection with novel coronavirus ( ncov) : Interim guidance v1 2019-ncov) technical guidance: Laboratory testing for 2019-ncov in humans Smartphonebased mobile detection platform for molecular diagnostics and spatiotemporal disease mapping Instrument-free point-of-care molecular detection of zika virus Twostage isothermal enzymatic amplification for concurrent multiplex molecular detection Chinese CDC, specific primers and probes for detection 2019 novel coronavirus Method for colorimetric detection of double-stranded nucleic acid using leuco triphenylmethane dyes Chest CT for typical 2019-nCoV pneumonia: Relationship to negative RT-PCR testing Smart cup: A minimally-instrumented, smartphone-based point-of-care molecular diagnostic device Closed-Tube, Molecular Test for the 2019 Novel Coronavirus (COVID-19) at Home, Clinic, and Points of Entry Coronavirus sequences used for alignment in this study COVID-2019 EPI_ISL_402120 Alveolar lavage fluid China COVID-2019 EPI_ISL_402121 Alveolar lavage fluid China COVID-2019 EPI_ISL_402126 Throat swab Japan COVID-2019 EPI_ISL_403932 Endotracheal aspirates China COVID-2019 EPI_ISL_403933 Endotracheal aspirates China COVID-2019 EPI_ISL_403936 Throat swab China COVID-2019 EPI_ISL_403937 Nasal swab China